Search Results
Your search for ,itS matches 8694 pages
Showing 401 - 450AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...
AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC
The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...
Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
WHI Funding Future Unclear
Women’s Health Initiative (WHI) investigators were informed on April 21 that the Department of Health and Human Services (HHS) will terminate WHI Regional Center (RC) contracts at the end of the current fiscal year (September 2025). The WHI Clinical Coordinating Center (CCC) will continue...
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Hyperefficient and Super-Digitized Health Care: Where Is the Smile?
A few weeks ago, a family member underwent a minor outpatient operative procedure. From a few weeks before the scheduled date of the procedure, multiple text messages and e-mails were forwarded to provide preparatory instructions for the procedure. The day before the procedure, another...
Is This the End of Cancer Research as We Know It?
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw made its way to facilities and administrative (F&A)...
Role of Pathologists in Improving Access to Safer, More Effective Allogeneic Cell Therapies
Researchers are working to accelerate the clinical adoption of novel allogeneic cell therapies to improve cancer care and treatment, according to a new report from the College of American Pathologists (CAP). Background Allogeneic cell therapy—which uses cells from a healthy donor rather than a...
Updated CAP Guideline Aims to Address Rising Rates of HPV-Associated Squamous Cell Carcinomas
The College of American Pathologists (CAP) updated its testing guideline to capture new research and emerging technologies to improve the diagnostic accuracy of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas, according to a guideline update published by Lewis et al in...
Metabolic Syndrome May Increase Risk of Cancer Recurrence, Subsequent Mortality Among Breast Cancer Survivors
Breast cancer survivors with metabolic syndrome may have an elevated likelihood of breast cancer recurrence and subsequent breast cancer–related mortality, according to new findings to be presented by Harborg et al at the European Congress on Obesity (ECO) 2025, taking place between May 11 and 14...
How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?
A recent study published by Hooda et al in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has significantly improved access to timely treatment and high-volume hospitals for patients with early-stage non–small cell lung cancer (NSCLC). These findings...
Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure
Individuals who reported exclusive use of combustible cigarettes as well as those who reported dual use of both cigarettes and e-cigarettes showed similarly high toxicant exposure, according to the results of a study published in Nicotine & Tobacco Research. Both groups of smokers showed higher ...
Parasitic Infection and Its Treatment Linked to Cancer-Related Gene Activity in the Cervix
New research has revealed that Schistosoma haematobium, a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment. Presented at ESCMID Global 2025, this pivotal study sheds new light ...
ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma
Investigators have identified a key component inhibiting responses to lenalidomide in patients with multiple myeloma, according to the results of a study recently published in Blood. They identified adenosine deaminase acting on RNA1 (ADAR1) as a novel driver of acquired resistance to lenalidomide...
Link Between CT Scans and Future Cancer Incidence?
At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...
FDA Approves Bevacizumab Biosimilar
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...
American Cancer Society Launches CEO Search
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) announced the launch of a nationwide search to find the organizations’ next Chief Executive Officer (CEO). In November, the ACS Board of Directors appointed Wayne A.I. Frederick, MD, MBA, to serve as...
Study Identifies Biologic Reasons for Selective Benefit of PARP Inhibitors
A newfound role for the cancer gene BRCA2 suggests why only select patients have benefited from treatment with PARP1 inhibitors to date. The results of a study by investigators at NYU Langone Health were recently published in the journal Nature. In brief, PARP inhibitors act by impairing...
Radiation Therapy: Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior...
Is Surgery Necessary to Treat Invasive Breast Cancer?
Surgery may not be necessary for patients with early-stage breast cancer who had a complete response to neoadjuvant chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center. Five-year results from the phase II...
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...
Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper tract urothelial carcinoma. Study Details In this multicenter open-label trial, 45...
Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP...
Parker Institute for Cancer Immunotherapy Names New CEO
The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...
Novel Limonene-Lipid Formulation May Help Alleviate Xerostomia in Patients With Cancer
When combined with a novel lipid formulation, a natural citrus essential oil from oranges, lemons, and limes—known as limonene—may prove to be effective in relieving xerostomia without significant adverse effects among patients with cancer, according to a recent study published by Wright et al in...
Lifetime Body Weight Patterns Could Affect Risk of Developing Renal Cell Carcinoma
Weight patterns throughout life may affect an individual’s likelihood of developing renal cell carcinoma, according to a recent study published by Deng et al in Cancer. Study Methods and Results In the study, investigators used data from the NIH-AARP Diet and Health Study to assess weight patterns...
Are New-Onset Type 2 Diabetes and Obesity-Related Cancers Linked?
A new diagnosis of type 2 diabetes may be linked to a subsequent increased risk of developing some obesity-related cancers, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Previous research has uncovered associations between type 2 diabetes and a...
Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?
Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced...
Sex Differences in Waist Circumference vs BMI as Risk Factors for Obesity-Related Cancers
Waist circumference may be a more effective risk marker for the development of obesity-related cancers than body mass index (BMI) in male but not female patients, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Body size and excess...
Microultrasound- vs MRI-Guided Biopsy for Prostate Cancer Diagnosis
Biopsies guided by high-resolution ultrasound may be as effective as those using magnetic resonance imaging (MRI) in diagnosing prostate cancer, an international clinical trial has shown. The technology, called micro-ultrasound, is cheaper and easier to use than MRI. It could significantly speed up ...
Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?
A simple urine test could accurately detect clear cell renal cell carcinoma (RCC) recurrence at an early stage, potentially sparing patients from undergoing invasive scans and enabling quicker access to treatment, according to new findings presented by Dabestani et al at the European Association of ...
Conundrums in Treating HER2-Positive Early Breast Cancer
Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...
Virtual Reality Therapy May Improve Chemotherapy-Associated Side Effects
A study conducted by Stansel et al, which was published in the journal Clinical Journal of Oncology Nursing, highlighted the potential of virtual reality therapy to reduce patient stress, pain, and negative affect during chemotherapy sessions. The findings also appeared to support its delivery and...
New Reports Assess Oncology Workforce Well-Being, Propose Solutions to Address Burnout
Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...
Results Announced From Phase II VERITAC-2 Clinical Trial in Breast Cancer
Arvinas, Inc. and Pfizer Inc. recently announced results from the randomized phase III VERITAC-2 clinical trial (ClinicalTrials.gov identifier NCT05654623) evaluating vepdegestrant monotherapy vs fulvestrant in adults with estrogen receptor–positive, HER2-negative advanced or metastatic breast...
Bringing Palliative Care to Every Patient With Cancer
Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.” —Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Benefit Suggested for Early Treatment of Advanced-Stage, Very Low–Tumor Burden Follicular Lymphoma
In the phase III JCOG1411/FLORA trial of patients with untreated advanced-stage, very low–tumor burden follicular lymphoma, rituximab induction delayed disease progression to high–tumor burden follicular lymphoma and delayed the initiation of cytotoxic chemotherapy, according to Japanese...
New Guideline Supports Transoral Robotic Surgery in the Multidisciplinary Management of Patients With Oropharyngeal Cancer
Transoral robotic surgery (TORS) can offer patients with oropharyngeal squamous cell carcinoma (OPSCC) improved survival while minimizing or avoiding late toxicities associated with the standard of care of radiation with cisplatin chemotherapy, according to a recent ASCO guideline.1 “We show in a...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
Benefit of Regular Physical Activity Prior to Cancer Diagnosis
Regular physical activity prior to a cancer diagnosis may be linked to a lower risk of disease progression and mortality, according to a recent study conducted by Professor Jon S. Patricios, MBBCh, of the University of Witwatersrand, Johannesburg, South Africa, and colleagues and published in the...
Monica M. Bertagnolli, MD, FACS, FASCO, Joins Friends of Cancer Research Board of Directors
Friends of Cancer Research (Friends) is honored to announce the addition of former Director of the National Institutes of Health (NIH) Monica M. Bertagnolli, MD, FACS, FASCO, to its Board of Directors. “Dr. Bertagnolli has built her incredible career around improving the lives of patients through...
Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
Circulating tumor DNA (ctDNA) has evolved from an experimental biomarker to an increasingly actionable tool, informing treatment decisions throughout colorectal cancer care. Whether guiding adjuvant therapy intensification or de-escalation, refining organ-preservation strategies in rectal cancer,...
Intraperitoneal Paclitaxel Combination Regimen Improves Overall Survival in Advanced Gastric Cancer
Adding intraperitoneal (IP) paclitaxel to standard intravenous (IV) paclitaxel plus S-1 (oral fluoropyrimidine derivative) significantly extended overall survival for patients with gastric cancer peritoneal metastases, according to data presented at the 2025 ASCO Gastrointestinal Cancers...
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets
The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk...
AI Tool May Help to Predict Which Patients With Prostate Cancer May Benefit From Focal Therapy
A novel artificial intelligence (AI) tool, called Unfold AI, may help to determine which men with prostate cancer are most likely to benefit from partial gland cryoablation, according to a recent study published by Brisbane et al in BJUI Compass. The findings may play a key role in improving...
Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?
With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...
The Real Cost Campaign May Have Prevented Thousands of Youths From Initiating E-Cigarette Use
The U.S. Food and Drug Administration’s (FDA) youth e-cigarette prevention campaign, known as The Real Cost, may have successfully reduced e-cigarette use among youth, according to a recent study published by MacMonegle et al in the American Journal of Preventive Medicine. Background The Real Cost...
